Safety and Efficacy in Randomized Controlled Trials of Second-Generation Antipsychotics Versus Placebo for Cognitive Impairments in Schizophrenia: A Meta-Analysis
J Clin Psychopharmacol
.
2022 Mar-Apr;42(2):227-229.
doi: 10.1097/JCP.0000000000001232.
Authors
Kazutaka Ohi
,
Yukimasa Muto
,
Shunsuke Sugiyama
,
Toshiki Shioiri
PMID:
32740555
DOI:
10.1097/JCP.0000000000001232
No abstract available
Publication types
Meta-Analysis
MeSH terms
Antipsychotic Agents*
Cognitive Dysfunction* / drug therapy
Cognitive Dysfunction* / etiology
Humans
Randomized Controlled Trials as Topic
Schizophrenia* / drug therapy
Substances
Antipsychotic Agents